Theralink Technologies Inc (THER)

[RetireSooner]

From: OncBioMune Corporate <[e-mail]>
Date: September 5, 2019 at 2:09:59 PM CDT
Subject: Re: [External] Major concerns as an investor

We had a CRO breach contract and are now working towards a resolution to determine the next steps.

Please see the following hyperlinks, which show what we are currently working on with PGT.

http://oncbiomune.com/2019/07/15/oncbiomune-announces-compelling-pre-clinical-data-for-its-cd71-targeted-chemotherapy-pgt-in-models-of-lung-pancreatic-and-ovarian-cancers/
http://oncbiomune.com/2019/05/30/oncbiomune-announces-initial-in-vitro-proof-of-concept-data-for-pgt-in-a-multi-drug-resistant-ovarian-cancer-model/

Thank you.

OBMP

On Sep 5, 2019, at 2:26 PM:

What is in the pipeline currently?

Sent from my iPhone

On Sep 5, 2019, at 1:16 PM, Bhatt,Rupal (HMFP - Dept of Medicine) <[e-mail]> wrote:

At this time, there are no plans to move this trial forward.

Rupal Bhatt

Sent: Thursday, September 5, 2019 2:14 PM
To: [e-mail]; Bhatt,Rupal (HMFP - Dept of Medicine); [e-mail]
Subject: [External] Major concerns as an investor

All, I have some major concerns regarding the lack of communication regarding the status and progress of NCT03579654, O17-11110, Study of Proscavax Vaccine in Patients With Localized Prostate Cancer vs Active Surveillance. Can you provide an update?

Additionally, if you go to https://www.otcmarkets.com/stock/OBMP/news the last news release that is listed is from 9/27/2018. However, there have been 12 press releases per http://oncbiomune.com/news/ since 9/27/2018. Although the stock price and volume seem to indicate that there is little to no interest in this study, I believe it may have be due to a the lack of awareness as Proscavax seems promising.